Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and L…
$14.15-6.14%
报价 2026-11-13
市值
$11.29B
EV
$12.9B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -46.4%
$12.43$26.38
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| SMMTSummit Therapeutics Inc. | $11.29B | -6.1% | -94.2% | 0% | – | – | – | |
| MRNAModerna, Inc. | $90.38B | -3.4% | +19.2% | -12.6% | – | – | – | |
| RPRXRoyalty Pharma plc | $30.86B | +0.8% | +17.6% | 100% | 25.6x | 17.1x | 10.4x | |
| ROIVRoivant Sciences Ltd. | $28.64B | -1.2% | – | 81.2% | – | – | – | |
| ASNDAscendis Pharma A/S | $18.06B | +3.1% | – | 86.3% | – | – | – | |
| BBIOBridgeBio Pharma, Inc. | $15.25B | +0.2% | +119.5% | 93.8% | – | – | – | |
| UHSUniversal Health Services, Inc. | $9.78B | +0.1% | +7.1% | 9.6% | 8.2x | 5.8x | 9.1x | Cheap |
| IONSIonis Pharmaceuticals, Inc. | $4.84B | +6.4% | +2.4% | 98.3% | – | 3.1x | – | |
| RNAAvidity Biosciences, Inc. | $162M | +0.1% | -61.9% | 100% | – | – | – | |
| 同行中位数 | – | – | +12.4% | 90% | 16.9x | 5.8x | 9.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。